The REPRISE study was conducted in late-stage ADPKD patients with chronic kidney disease as part of the tolvaptan clinical development program. It enrolled over 1,300 patients from 213 centres across 21 countries, including 6 centres in Canada. The results of the REPRISE study were announced on November 4 at the ASN Kidney Week 2017 in New Orleans. The REPRISE Study already appears in the New England Journal of Medicine with an accompanying editorial (Article, Editorial). 

Watch the videos at UKidney Internet School of Nephrology for expert reactions from Canadian nephrologists Dr. Louis Girard, Dr. Daniel Bichet and Dr. Daniel Sapir.

Read our blog post that announces the findings from the trial’s results here.